An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 31 May 2017 Status changed from active, no longer recruiting to completed.
- 16 Mar 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2017, according to ClinicalTrials.gov record.
- 16 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.